ReviewFrontiers in oncology2022
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Genetic testing practices among specialist physicians who treat prostate cancer Updated survey of Canadian practitioners.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans.The oncologist · 2026Article
- Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.Future oncology (London, England) · 2026Article
- Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoring.Frontiers in molecular medicine · 2026Review
- Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?Current oncology (Toronto, Ont.) · 2025Review
- Article
- Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.Molecular oncology · 2025Article
- BRCA Mutation Testing in Men With Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice.Asia-Pacific journal of clinical oncology · 2025Review
- Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances.The journal of liquid biopsy · 2025Review
- Advances in the treatment of metastatic prostate cancer in China.Cancer biology & medicine · 2025Article
- Review
- Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management.Current treatment options in oncology · 2024Review
- Comparison of discovery rates and prognostic utility of [European journal of nuclear medicine and molecular imaging · 2024Article
- Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.JCO precision oncology · 2024Article
- Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.Nature communications · 2024Article
- Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis.Therapeutic advances in medical oncology · 2024Article
- Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.Cancers · 2023Article
- Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.Oncoscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine clinical care. In this review, we summarize current and emerging applications for ctDNA analysis in metastatic prostate cancer, including outcome prediction, treatment selection, and characterization of treatment resistance. We also discuss potential pitfalls with interpreting ctDNA findings, namely false negatives arising from low tumor content and optimal assay design, including correction for clonal hematopoiesis of indeterminate potential and germline variants. Understanding the influence of these limitations on interpretation of ctDNA results is necessary to overcome barriers to clinical implementation. Nevertheless, as assay availability and technology continue to improve, recognizing both opportunities and shortcomings of ctDNA analysis will retain relevance with informing the implementation of precision-oncology initiatives for metastatic prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.